Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPSC-derived CD2-targeted CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Vrije University Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
iPSC-derived CD2-targeted CAR-T cells are a novel form of engineered cell therapy in which induced pluripotent stem cells (iPSCs) are genetically modified to express a chimeric antigen receptor (CAR) that specifically targets the CD2 molecule. The process begins with reprogramming donor somatic cells into iPSCs, which can then be expanded indefinitely and differentiated into T-cells. These T-cells are further engineered to express a synthetic CAR targeting the surface protein CD2, enabling them to recognize and kill target cells expressing this antigen. This approach allows for scalable "off-the-shelf" manufacturing of therapeutic T-cells with uniform properties and potentially reduced risk of immune rejection compared to conventional autologous or allogeneic approaches[5][4][2]. The technology is still in early development but holds promise for treating cancers or other diseases where targeting CD2-expressing cells is beneficial.
- Other names
- induced pluripotent stem cell derived CD2-targeted chimeric antigen receptor T cellsiPSC-CD2 CAR-TiPSC-CD-2 CAR-TiPSC-CD 2 CAR-T
02
Targets
CD2 (T-cell Surface Antigen CD2)
Beyond the preview
Go deeper on iPSC-derived CD2-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPSC-derived CD2-targeted CAR-T cells.